Shanghai Institute of Technology, Shanghai, China.
School of Pharmacy, Fudan University, Shanghai, China.
J Pharm Pharmacol. 2018 Sep;70(9):1139-1151. doi: 10.1111/jphp.12940. Epub 2018 Jun 21.
Recent years, gene therapy to treat retinal diseases has been paid much attention. The key to successful therapy is utilizing smart delivery system to achieve efficient gene delivery and transfection. In this study, hyaluronic acid (HA) modified cationic niosomes (HA-C-niosomes) have been designed in order to achieve retinal pigment epithelium (RPE) cells targeted gene delivery and efficient gene transfection.
Cationic niosomes composed of tween 80/squalene/1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) were prepared by the ethanol injection method. After that, HA-DOPE was further added into cationic niosomes to form HA-C-niosomes. Cellular uptake and transfection have been investigated in ARPE-19 cells. In vivo pEGFP transfection efficiency was evaluated in rats.
Twenty percentage HA-C-niosomes were about 180 nm, with -30 mV, and showing spherical shape in TEM. 2 times higher transfection efficiency was found in the group of HA-C-niosomes with 20% HA modification. No toxicity was found in niosome preparations. In vivo evaluation in Sprague Dawley (SD) rats revealed that HA-C-niosomes could specifically target to the retina layer. In the group of pEGFP-loaded HA-C-niosomes, 6-6.5 times higher gene transfection has been achieved, compared with naked pEGFP.
Hyaluronic acid-C-niosomes might provide a promising gene delivery system for successful retinal gene therapy.
近年来,基因治疗治疗视网膜疾病受到了广泛关注。成功治疗的关键是利用智能递药系统实现高效的基因递药和转染。在本研究中,设计了透明质酸(HA)修饰的阳离子脂质体(HA-C-脂质体),以实现视网膜色素上皮(RPE)细胞的靶向基因递药和高效基因转染。
采用乙醇注入法制备由吐温 80/角鲨烯/1,2-二油酰基-3-三甲铵丙烷(DOTAP)组成的阳离子脂质体。然后,将 HA-DOPE 进一步加入阳离子脂质体中形成 HA-C-脂质体。在 ARPE-19 细胞中研究了细胞摄取和转染。在大鼠体内评估了 pEGFP 的转染效率。
20%HA-C-脂质体的粒径约为 180nm,Zeta 电位为-30mV,TEM 显示为球形。经 20%HA 修饰的 HA-C-脂质体的转染效率提高了 2 倍。脂质体制剂无毒性。在 Sprague Dawley(SD)大鼠体内评价表明,HA-C-脂质体能够特异性靶向视网膜层。在 pEGFP 负载的 HA-C-脂质体组中,与裸 pEGFP 相比,基因转染效率提高了 6-6.5 倍。
透明质酸-C-脂质体可为成功的视网膜基因治疗提供有前途的基因递药系统。